Skip to main content
Premium Trial:

Request an Annual Quote

Gran Ando, Kevin Ryan, Ronald Artale, Wesley Jessen, Kenneth Standing, Werner Ens, Raymond Dwek, Max Burger, Donald Drakeman, Peter Allen, John Slater, Peter Nicholls, Ian Nicholson, Jonathan Glenn, Andrew Weir

Premium

As widely expected in the industry, Göran Ando has been appointed CEO of Slough, UK-based Celltech, replacing Peter Fellner, who will serve as the company’s chairman. Ando joins the company from Pharmacia, which was recently acquired by Pfizer, where he was president of R&D and an executive vice president. Previously, he was R&D director for Glaxo Group Research. He also held positions at Astra Research Centre, Bristol-Myers International Group, and Pfizer. Ando has an MD from Linkoping Medical University in Sweden.

 

Kevin Ryan has become president and CEO of Large Scale Biology. He replaces Robert Erwin as CEO, who will remain with the company as chairman of the board and head of its scientific advisory board, and John Fowler as president, who will remain a director of LSBC through the current term. Fowler will join Baycrest Capital, a private investment firm. LSBC’s senior vice president and CFO Ronald Artale has also become COO. Ryan already held the position of LSBC’s president from 1991 until 1995, when he became CEO of contact lens manufacturer Wesley Jessen.

 

Miraculins of Winnipeg, Manitoba, has appointed Kenneth Standing and Werner Ens as founding members of its scientific advisory board. Standing is professor emeritus in the department of physics at the University of Manitoba. He holds a BSc from the University of Manitoba and a PhD from Princeton University. Ens is also a professor in the department of physics, as well as the co-director of the Manitoba Centre for Proteomics. He holds a PhD in physics from the University of Manitoba. Standing and Ens jointly run the university’s Time-of-Flight Mass Spectrometry Laboratory.

 

One day after Celltech declared its offer for Oxford GlycoSciences unconditional (see p.1), Raymond Dwek, Max Burger, and Donald Drakeman resigned from the board of OGS. The same day, the company appointed

Peter Allen

, John Slater, Peter Nicholls, Ian Nicholson, Jonathan Glenn and Andrew Weir as non-executive directors to its board.

 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.